Bermekimab

Summary

Bermekimab (CHEMBL2109653) is a phase-3 clinical-stage antibody (ATC L01FX11); indicated across 12 conditions including neoplasm and colorectal adenocarcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• ATC class: L01FX11
• Indications: 12 conditions
• Clinical trials: 15

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2109653
Name	Bermekimab
Type	Antibody
Max phase	3
ATC	L01FX11

Also known as: Bermekimab, CA-18C3, CV-18C3, MaBp1, RA-18C3, Xilonix, BERMEKIMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

12 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	3	MONDO:0005070	EFO:0000616
colorectal adenocarcinoma	3	MONDO:0005008	EFO:0000365
colorectal neoplasm	3	MONDO:0005335	MONDO:0005575
acne	2	MONDO:0011438	EFO:0003894
pyoderma	2	MONDO:0002922	HP:0000999
psoriasis	2	MONDO:0005083	EFO:0000676
hidradenitis suppurativa	2	MONDO:0006559	EFO:1000710
atopic eczema	2	MONDO:0004980	EFO:0000274
systemic sclerosis	2	MONDO:0005100	EFO:0000717
type 2 diabetes mellitus	2	MONDO:0005148	MONDO:0005148

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 15.

Phase distribution

Phase	Trials
PHASE2	10
PHASE1	3
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01767857	PHASE3	TERMINATED	A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
NCT02138422	PHASE3	COMPLETED	A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer
NCT01270945	PHASE2	COMPLETED	Safety and Preliminary Efficacy Study of an Anti-inflammatory Therapeutic Antibody in Reducing Restenosis.
NCT01384630	PHASE2	COMPLETED	Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis
NCT01474798	PHASE2	COMPLETED	Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris
NCT01965613	PHASE2	COMPLETED	A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum
NCT02643654	PHASE2	COMPLETED	MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB
NCT04019041	PHASE2	COMPLETED	A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa
NCT04045743	PHASE2	COMPLETED	The Benefit of Bermekimab in Patients With Systemic Sclerosis
NCT04791319	PHASE2	TERMINATED	A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis
NCT04988308	PHASE2	TERMINATED	A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa
NCT04990440	PHASE2	TERMINATED	A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT01021072	PHASE1	COMPLETED	A First in Man Study of MABp1 in Patients With Advanced Cancers
NCT01260545	PHASE1	COMPLETED	Study of CA-18C3 in Subjects With Advanced Hematologic Malignancies
NCT03047317	PHASE1	COMPLETED	A Pharmacokinetic Study of MABp1 in Healthy Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).